In SFJD alone or combined with oseltamivir for the treatment of chronic obstructive pulmonary disease induced by influenza A virus, SFJDC alone and combined with oseltamivir were found to control airway inflammation and lung injury in IAV-infected rats by modulating NLRP3 inflammatory vesicles and subsequently downregulating IL-1β and IL-18 (15). This evidence concerns the gene IL18 and chronic obstructive pulmonary disease.